SCHEMBL3961023

SCHEMBL3961023

CCOC(=O)c1[nH]c2ncc(NS(=O)(=O)c3ccc(-c4ccccc4)cc3)cc2c1-c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.52
TP53 P04637 4/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
THRB P10828 1/20 0.52
PIK3CD O00329 1/20 0.47
PIK3R1 P27986 1/20 0.47
PIK3CA P42336 1/20 0.47
PIK3CB P42338 1/20 0.47
PIK3CG P48736 1/20 0.47
ACR P10323 1/20 0.47
ALDH1A1 P00352 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C19 P33261 2/20 0.47
HPGD P15428 1/20 0.47
XBP1 P17861 1/20 0.47
NPSR1 Q6W5P4 2/20 0.47
FABP1 P07148 1/20 0.46
HTT P42858 1/20 0.46
HIF1A Q16665 1/20 0.46
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3957157 0.92 HIF1A (0.52) MAPTTP53SMN1; SMN2THRBPIK3CD
SCHEMBL4133133 0.91 HIF1A (0.53) MAPTTP53SMN1; SMN2THRBPIK3CD
SCHEMBL3958851 0.90 SERPINE1 (0.51) MAPTTP53SMN1; SMN2THRBPIK3CD
SCHEMBL3958387 0.86 SERPINE1 (0.49) PIK3CAALDH1A1HPGDFABP1HTT
SCHEMBL4078804 0.85 MAPT (0.47) MAPTTP53SMN1; SMN2THRBPIK3CD
SCHEMBL3955112 0.84 MAP2 (0.60) PIK3CAFABP1AURKAAURKBSERPINE1
SCHEMBL13872830 0.80 ALDH1A1 (0.56) MAPTTP53SMN1; SMN2ALDH1A1CYP1A2
SCHEMBL4070333 0.79 FABP1 (0.45) PIK3CAPIK3CGALDH1A1FABP1KDM4E
SCHEMBL4586922 0.79 ALDH1A1 (0.56) MAPTTP53SMN1; SMN2THRBALDH1A1
SCHEMBL3957017 0.79 SERPINE1 (0.54) MAPTSMN1; SMN2PIK3CAALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090098189-A1 AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE BAYER SCHERING PHARMA AG (DE) 2009-04-16 US disclosed
US-20090098189-A1 AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE BAYER SCHERING PHARMA AG (DE) 2009-04-16 US disclosed
US-20090098189-A1 AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE BAYER SCHERING PHARMA AG (DE) 2009-04-16 US disclosed
EP-2036906-A1 Azaindoles as inhibitors of soluble adenylate cyclase Bayer Schering Pharma Aktiengesellschaft (DE) 2009-03-18 EP disclosed
WO-2009030725-A2 AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-03-12 WO disclosed
WO-2009030725-A2 AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090098189-A1 AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE ADCY1, ADCY5, ADCY2 MAPT 4758/4885TP53 3206/4885SMN1; SMN2 4433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.